Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Exclusive: Ernst, audit clients cut lobbying ties-records

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:11am CEST
Entrances to the offices of Ernst & Young is seen in New York

WASHINGTON/NEW YORK (Reuters) - Ernst & Young's lobbying unit is no longer listed as a lobbyist for three major U.S. companies, all of whom were 2011 audit clients of the accounting giant. The deregistration follows questions raised by two U.S. senators in March about whether the dual relationships crossed auditor independence boundaries.

Documents filed last month with Congress showed that Washington Council Ernst & Young, the E&Y unit, was no longer registered as doing lobbying work for Amgen Inc (>> Amgen, Inc.), CVS Caremark Corp (>> CVS Caremark Corporation) and Verizon Communications Inc (>> Verizon Communications Inc.).

A lobbying-contract termination was also filed on March 31 for a fourth company, Nomura Holdings Inc (>> Nomura Holdings Inc.), which, according to securities filings, uses an E&Y affiliate for auditing services. E&Y had provided lobbying services to Nomura since June 2011, according papers on file with Congress.

Auditors that review corporations' books every year must follow rules limiting other ties with audit clients. The rules - meant to prevent auditors from getting too cozy with audit clients - were substantially beefed up a decade ago after a rash of accounting scandals at Enron Corp. and other companies.

An Ernst & Young spokesman declined to comment on the discontinued lobbying relationships. Officials with Nomura, Verizon and CVS declined to comment. Amgen officials could not immediately be reached for comment.

The chief accountant for the U.S. Securities and Exchange Commission, James Kroeker, speaking at a financial reporting conference at Baruch College in New York on Thursday, said SEC rules state an auditor should not act in an advocacy role for a company it audits and lobbying would be inconsistent with that.

Kroeker did not mention any audit firms by name.

He said: "If you think about lobbying in the traditional sense, you would say, 'wouldn't somebody that's lobbying be placing themselves in a position to be an advocate?'"

Asked whether the SEC was looking into E&Y's lobbying activities, an official in the agency's enforcement division declined to comment because its investigations are not public.

"We are aware of it and we are cognizant of what the rules are," said Howard Scheck, chief accountant of the SEC's division of enforcement, on the sidelines of Thursday's conference.

"If there's a violation that we find, we'll certainly do something about that," he said, without referring to E&Y.

Reuters reported in March that Washington Council Ernst & Young had been hired as a lobbyist for a number of E&Y's audit clients, prompting two lawmakers to demand closer scrutiny.

Democratic senators Carl Levin and Jack Reed both expressed concerns at the time and urged the SEC to look into the matter. On Thursday, Reed's office did not immediately respond to inquiries seeking comment. Levin's office declined to comment.

Verizon had a particularly long relationship with E&Y's lobbyists, who helped the telecommunications company with tax issues beginning in September 2001. The two other lobbying relationships were more recent, dating to February in the case of Amgen and September in the case of CVS Caremark. Both contracts were connected to corporate tax debates. The three U.S. terminations were all effective March 31 and Nomura's termination was filed the same day.

The E&Y spokesman referred Reuters to its earlier statement that Washington Council's work complied with independence rules.

The work was approved by clients' audit committees and it was limited to tax-related issues, E&Y spokesman Charles Perkins said when Reuters reported on the issue in March.

Washington Council did not solicit votes on legislation for E&Y audit clients, Perkins said.

The Public Company Accounting Oversight Board, the watchdog for U.S. auditors, is looking to shore up independence rules after finding numerous instances in which auditors did not dig deeply enough to challenge clients' financial numbers.

The SEC's Kroeker said he was encouraged to see the board tackling the subject.

"Independence is really the bedrock, the foundation of the value that's provided by a third-party audit," he said.

(Reporting by Dena Aubin and David Ingram; Additional reporting by Kim Dixon; Editing by Kevin Drawbaugh and Matt Driskill)

By David Ingram and Dena Aubin

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN -0.79% 171.56 Delayed Quote.-0.56%
CVS HEALTH -0.37% 65.12 Delayed Quote.-9.16%
NOMURA HOLDINGS INC 0.09% 637 End-of-day quote.-5.89%
VERIZON COMMUNICATIONS -1.09% 47.9 Delayed Quote.-8.50%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
04/20CVS HEALTH CORPORATION : To Hold First Quarter 2018 Conference Call
PR
04/20CVS PHARMACY : Offering Hepatitis A Vaccine to Kentuckians Following an Increase..
PR
04/20CVS HEALTH : Ex-dividend day for
FA
04/19CVS HEALTH : Expands Safe Drug Disposal at CVS Pharmacy Locations in Ohio to Hel..
PR
04/19CVS PHARMACY : Launches First Campaign Featuring Unaltered Beauty Imagery
PR
04/19CVS HEALTH : EX-Dividend Schedule: CVS Health Has a Dividend Yield of 3.03%; Wil..
AC
04/18CVS HEALTH : Phoenix VA Health Care System, TriWest and CVS Health Mark First An..
PR
04/18CVS HEALTH : Names Marc-David Munk, MD, MPH, MHCM, as Chief Medical Officer of M..
AQ
04/17UnitedHealth earnings ease investor worries over flu season, stock up
RE
04/17CVS HEALTH : Today’s Research Reports on Trending Tickers: CVS Health and Centen..
AC
More news
News from SeekingAlpha
08:38aTHE PASSIVE DGI CORE PORTFOLIO : Income, Safety, And Growth 
04/20Vilas Fund, LP Q1 '18 Letter To Partners - #28 Since Inception, Long Pharma 
04/1910 Dividend Growth Stocks For April 2018 
04/19Jelly Beans, Group Think, And Greenblatt's Magic Formula 
04/193 Cheap Dividend Stocks To Consider 
Financials ($)
Sales 2018 189 B
EBIT 2018 10 003 M
Net income 2018 5 761 M
Debt 2018 20 873 M
Yield 2018 3,31%
P/E ratio 2018 11,98
P/E ratio 2019 10,66
EV / Sales 2018 0,46x
EV / Sales 2019 0,43x
Capitalization 66 066 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 87,9 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-9.16%66 066
WALGREENS BOOTS ALLIANCE-10.11%63 387
EXPRESS SCRIPTS HOLDING CO-1.54%41 267
MCKESSON CORPORATION-5.67%30 177
AMERISOURCEBERGEN-0.14%19 742
CARDINAL HEALTH1.70%19 534